Prognosis of patients with familial hypercholesterolemia after acute coronary syndromes. Circulation. 2016;134:698 709. S4.3-23. Perak AM, Ning H, de Ferranti SD, et al. Long-term risk of atheroscle- rotic cardiovascular disease in US adults with the familial hypercho- lesterolemia phenotype. Circulation. 2016;134:9 19. S4.3-24. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301 7. S4.3-25. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ. 2008;337:a2423. S4.3-26. Mortensen MB, Fuster V, Muntendam P, et al. A simple disease- guided approach to personalize ACC/AHA-recommended statin allocation in elderly people: the BioImage Study. J Am Coll Cardiol. 2016;68:881 91. S4.3-27. Willeit P, Kiechl S, Kronenberg F, et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospec- tive 15-year outcomes in the Bruneck Study. J Am Coll Cardiol. 2014;64:851 60. S4.3-28. Nasir K, Bittencourt MS, Blaha MJ, et al. Implications of coro- nary artery calcium testing among statin candidates according to American College of Cardiology/American Heart Association cho- lesterol management guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2015;66:1657 68. S4.3-29. Ridker PM, Mora S, Rose L, et al. Percent reduction in LDL choles- terol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. Eur Heart J. 2016;37:1373 9. S4.3-30. Yano Y, O Donnell CJ, Kuller L, et al. Association of coronary artery calcium score vs age with cardiovascular risk in older adults: an analysis of pooled population-based studies. JAMA Cardiol. 2017;2:986 94. S4.3-31. Malik S, Zhao Y, Budoff M, et al. 